

Press Release

VENTURA GLOBAL shares encouraging news regarding treatment of Covid-19

It is always a pleasure to learn of our customers success and achievements, especially when they touch the lives of many and help humanity at large. Let me share with you a story in current development that makes us particularly hopeful and proud.

“MAD Lab” is not a Crazy Lab but the Monoclonal Antibody Discovery Laboratory of the Toscana Life Sciences Foundation (one of our good Italian customers since 2016) which from March 2020 has been fully devoted to discovering a monoclonal antibody (mAb)-based treatment against the novel Coronavirus. As they have found promising mAb candidates and are starting clinical trials, the local and international press has bestowed them plenty of well-deserved attention. Their ultimate goal is to develop a treatment that can be delivered as a spray but first they are focusing on an injectable single-dose treatment. Target date for mass production is the Spring 2021.

Introductory video “SARS CoV-2: Identikit of a Killer” (aired by RAI 3: [PresaDiretta](#), in Italian)

This video explains how the MAD Lab identified their therapeutical mAb candidates (aired by RAI 1: [Porta-a-Porta](#), in Italian)

The article “The Race Against Covid-19” illustrates the research activity and some of the technologies utilized by the MAD Lab in this scientific endeavor (published in the [HP Innovation Magazine](#), in English)

VENTURA GLOBAL condivide notizie incoraggianti sul trattamento del Covid-19

È sempre un piacere conoscere il successo e i traguardi raggiunti dei nostri clienti, soprattutto quando toccano la vita di molti e aiutano l'umanità in generale. Permettetemi di condividere con voi una storia in corso di sviluppo che ci rende particolarmente fiduciosi e orgogliosi.

“MAD Lab” non è un laboratorio pazzo ma il Monoclonal Antibody Discovery Laboratory della Fondazione Toscana Life Sciences (uno dei nostri buoni clienti italiani sin dal 2016) che da marzo 2020 è completamente dedicato alla ricerca di una cura basata su anticorpi monoclonali (mAb) contro il nuovo Coronavirus. Poiché hanno trovato candidati mAb promettenti e stanno avviando sperimentazioni cliniche, la stampa locale e internazionale ha recentemente riservato loro una meritata attenzione. Il loro obiettivo finale è sviluppare un trattamento che possa essere somministrato come spray, ma prima si stanno concentrando su un trattamento a dose singola iniettabile. La data prevista per la produzione di massa è la primavera del 2021.

Video introduttivo "SARS CoV-2: Identikit of a Killer" (trasmissione di RAI 3: [PresaDiretta](#), in italiano)

Questo video spiega come il MAD Lab ha identificato i propri candidati terapeutici mAb (trasmissione di RAI 1: [Porta-a-Porta](#), in italiano)

L'articolo "The Race Against Covid-19" illustra l'attività di Ricerca & Sviluppo del MAD Lab in merito a questa investigazione scientifica (pubblicato su [HP Innovation Magazine](#), in inglese)

2020.11.18

p.1/2

Press Release (cont.)

VENTURA GLOBAL comparte noticias alentadoras sobre el tratamiento de Covid-19

Siempre es un placer conocer el éxito y los logros de nuestros clientes, especialmente cuando pueden mejorar la vida de muchos y ayudar a la humanidad en general. Permítanme compartir con ustedes una historia en desarrollo actual que nos llena de esperanza y orgullo.

“MAD Lab” no es un laboratorio loco sino el Monoclonal Antibody Discovery Laboratory de la Fundación Toscana Life Sciences (uno de nuestros buenos clientes italianos desde el 2016) que desde marzo del 2020 se ha dedicado de lleno a la búsqueda de un tratamiento basado en anticuerpos monoclonales (mAb) contra el nuevo Coronavirus. Habiendo encontrado candidatos mAb prometedores e iniciado ensayos clínicos, la prensa local e internacional les ha prestado merecida atención últimamente. El objetivo final de esta investigación es desarrollar un tratamiento que se pueda administrar en forma de aerosol, pero primero se están enfocando en un tratamiento de dosis única inyectable. La fecha prevista para la producción en masa es la primavera del 2021.

Video introductorio “SARS CoV-2: Identikit of a Killer” (transmitido por RAI 3: [PresaDiretta](#), en italiano)

Este video explica cómo el MAD Lab identificó a los candidatos terapéuticos mAb (transmitido por RAI 1: [Porta-a-Porta](#), en italiano)

El artículo “The Race Against Covid-19” ilustra la actividad de I+D y algunas de las tecnologías utilizadas por el MAD Lab en esta investigación científica (publicado en la revista [HP Innovation Magazine](#), en inglés)

About Ventura Global

VENTURA Global (VG) specializes in financial solutions for the procurement of new and used laboratory instrumentation. VG develops proposals, negotiates conditions, processes applications, and delivers Funder approved operational leasing agreements for Users to procure new and used laboratory equipment. To ensure timely completion of the transaction, VG takes ownership of the entire process and its documentation trail from proposals to the signed agreement and acceptance certificate to activate the leasing contract. As technology continuously evolves and as Users’ applications and market requirements change, there is a growing interest in upgrading or replacing the instruments near the end of their life cycle. VENTURA Global tailor-made solutions facilitate the purchase or replacement, upgrade, or extension of use for the instrumentation under contract. This technology renewal cycle also creates unique opportunities to acquire used equipment at very attractive conditions, ideally suited for those applications where state of the art equipment may not be required and where the budget is limited.

For additional information contact:

Gianni Fior

gfior@venturaglobal.com

2020.11.18

p.2/2